Prognosis in patients with carcinoid and pancreatic endocrine tumors with diffuse, unresectable liver metastases is poor. Palliation is often difficult despite the use of somatostatin analogs, interferon alpha, or systemic chemotherapy. Several reviews have suggested that hepatic artery embolization, with or without intraarterial chemotherapy, can be used for control of symptoms and for cytoreduction in patients with liver-dominant metastases.
Methods
Between 2000 and 2002, 161 embolizations using polyvinyl alcohol or microspheres were performed on 84 patients with carcinoid or pancreatic endocrine tumors metastatic to the liver. A retrospective review was performed to evaluate symptomatic response, biochemical response, adverse effects, and duration of survival. Baseline and follow-up computed tomography scans were also assessed to determine radiographic response rates. Further analysis of survival was performed to assess the possible impact of various postembolization therapies.
Results
Eighty-four patients underwent bland hepatic artery embolizations during the study period. Among 55 symptomatic patients, 44 patients had fewer symptoms, and among 35 patients whose tumor markers were followed, 28 had a major biochemical response. Objective radiographic responses were observed in 11 of 23 patients. No deaths occurred during therapy, and major toxicities were rare. Median overall survival was 36 months from time of initial embolization.
Conclusions
Hepatic artery embolization frequently results in clinical and radiographic responses in patients with unresectable liver metastases from carcinoid or pancreatic endocrine tumors. Morbidity is low when appropriate supportive care is provided.
References
1.
MoertelC.G.Karnofsky memorial lecture: an odyssey in the land of small tumors. J Clin Oncol.1987; 5: 1502–1522.
2.
NorheimI., ObergK., Theodorsson-NorheimE.Malignant carcinoid tumors: an analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg.1987; 206: 115–125.
3.
GuptaS., YaoJ.C., AhrarK.Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M. D. Anderson experience. Cancer J.2003; 9: 261–267.
4.
YaoK.A., TalamontiM.S., NemcekA.Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery.2001; 130: 677–685.
5.
QueF.G., NagorneyD.M., BattsK.P.Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg.1995; 169: 36–43.
6.
McEnteeG.P., NagorneyD.M., KvolsL.K.Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery.1990; 108: 1091–1096.
7.
SarmientoJ.M., HeywoodG., RubinJ.Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg.2003; 197: 29–37.
8.
DoussetB., Saint-MarcO., PitreJ.Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg.1996; 20: 908–915.
9.
KulkeM.H., MayerR.J.Carcinoid tumors. N Engl J Med.1999; 340: 858–868.
10.
O'TooleD., MaireF., RuszniewskiP.Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer.2003; 10: 463–468.
11.
NortonJ.A., WarrenR.S., KellyM.G.Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery.2003; 134: 1057–1065.
12.
GulecS.A., MountcastleT.S., FreyD.Cytoreductive surgery in patients with advanced-stage carcinoid tumors. Am Surg.2002; 68: 667–672.
13.
ChungM.H., PisegnaJ., SpirtM.Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery.2001; 130: 954–962.
14.
HellmanP., LadjevardiS., SkogseidB.Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg.2002; 26: 1052–1056. Epub 2002 May 21.
15.
GillamsA., CassoniA., ConwayG.Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging.2005; 30: 435–441.
16.
RuszniewskiP., O'TooleD.Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology.2004; 80(suppl 1): 74–78.
17.
HennA.R., LevineE.A., McNultyW.Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. AJR Am J Roentgenol.2003; 181: 1005–1010.
18.
MazziottiA., GraziG.L., GardiniA.An appraisal of percutaneous treatment of liver metastases. Liver Transpl Surg.1998; 4: 271–275.
19.
SutcliffeR., MaguireD., RamageJ.Management of neuroendocrine liver metastases. Am J Surg.2004; 187: 39–46.
20.
DoussetB., HoussinD., SoubraneO.Metastatic endocrine tumors: is there a place for liver transplantation?Liver Transpl Surg.1995; 1: 111–117.
21.
KvolsL.K.Metastatic carcinoid tumors and the carcinoid syndrome: a selective review of chemotherapy and hormonal therapy. Am J Med.1986; 81: 49–55.
22.
KvolsL.K., BuckM.Chemotherapy of endocrine malignancies: a review. Semin Oncol.1987; 14: 343–353.
23.
MoertelC.G.Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol.1983; 1: 727–740.
24.
MoertelC.G., RubinJ., KvolsL.K.Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol.1989; 7: 865–868.
25.
EngstromP.F., LavinP.T., MoertelC.G.Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol.1984; 2: 1255–1259.
26.
ChengP.N., SaltzL.B.Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer.1999; 86: 944–948.
27.
van HazelG.A., RubinJ., MoertelC.G.Treatment of metastatic carcinoid tumor with dactinomycin or dacarbazine. Cancer Treat Rep.1983; 67: 583–585.
28.
Di BartolomeoM., BajettaE., BochicchioA.M.A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours: a study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol.1995; 6: 77–79.
29.
FaissS., PapeU.F., BohmigM.Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors: the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol.2003; 21: 2689–2696.
30.
ObergK.Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol.1993; 5: 110–120.
31.
ObergK., ErikssonB.The role of interferons in the management of carcinoid tumours. Br J Haematol.1991; 79(suppl 1): 74–77.
32.
ObergK., NorheimI., LundqvistG.Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin: alone or in combination with 5-FU. Acta Oncol.1987; 26: 429–432.
33.
ObergK., NorheimI., LindE.Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results. Cancer Treat Rep.1986; 70: 1297–1304.
34.
ObergK., NorheimI., AlmG.Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon. Eur J Cancer Clin Oncol.1989; 25: 1475–1479.
35.
ObergK., FunaK., AlmG.Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med.1983; 309: 129–133.
36.
SchoberC., SchmollE., SchmollH.J.Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours. Eur J Cancer.1992; 28A: 1664–1666.
37.
BajettaE., ZilemboN., Di BartolomeoM.Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferonalpha-2a: a study by the Italian Trials in Medical Oncology Group. Cancer.1993; 72: 3099–3105.
38.
ValimakiM., JarvinenH., SalmelaP.Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?Cancer.1991; 67: 547–549.
39.
MoertelC.G., HanleyJ.A., JohnsonL.A.Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med.1980; 303: 1189–1194.
40.
KouvarakiM.A., AjaniJ.A., HoffP.Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol.2004; 22: 4762–4771. Erratum in: J Clin Oncol. 2005; 23: 248.
41.
MoertelC.G., LefkopouloM., LipsitzS.Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med.1992; 326: 519–523.
42.
RamanathanR.K., CnaanA., HahnR.G.Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma: study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol.2001; 12: 1139–1143.
43.
KvolsL.K., MoertelC.G., O'ConnellM.J.Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med.1986; 315: 663–666.
44.
LambertsS.W., van der LelyA.J., de HerderW.W.Octreotide. N Engl J Med.1996; 334: 246–254.
45.
ObergK., KvolsL., CaplinM.Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol.2004; 15: 966–973.
46.
KvolsL.K., MartinJ.K., MarshH.M.Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med.1985; 313: 1229–1230.
47.
WymengaA.N., ErikssonB., SalmelaP.I.Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol.1999; 17: 1111.
48.
SaltzL., TrochanowskiB., BuckleyM.Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer.1993; 72: 244–248.
49.
ArnoldR., TrautmannM.E., CreutzfeldtW.Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut.1996; 38: 430–438.
50.
ArnoldR., WiedM., BehrT.H.Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opin Pharmacother.2002; 3: 643–656.
51.
RuszniewskiP., RougierP., RocheA.Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors: a prospective phase II study in 24 patients. Cancer.1993; 71: 2624–2630.
52.
MoertelC.G., JohnsonC.M., McKusickM.A.The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med.1994; 120: 302–309.
53.
ErikssonB.K., LarssonE.G., SkogseidB.M.Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer.1998; 83: 2293–2301.
54.
LoeweC., SchindlM., CejnaM.Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol.2003; 180: 1379–1384.
55.
MittyH.A., WarnerR.R., NewmanL.H.Control of carcinoid syndrome with hepatic artery embolization. Radiology.1985; 155: 623–626.
DiamandidouE., AjaniJ.A., YangD.J.Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol.1998; 170: 339–344.
58.
DiacoD.S., HajarizadehH., MuellerC.R.Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intraarterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg.1995; 169: 523–528.
59.
MoertelC.G., KvolsL.K., O'ConnellM.J.Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer.1991; 68: 227–232.
60.
ObergK., ErikssonB.Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab.2005; 19: 265–276.
